ASP1128 + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Kidney Injury (AKI)
Conditions
Acute Kidney Injury (AKI)
Trial Timeline
Nov 1, 2019 → Oct 20, 2021
NCT ID
NCT03941483About ASP1128 + Placebo
ASP1128 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Acute Kidney Injury (AKI). The current trial status is completed. This product is registered under clinical trial identifier NCT03941483. Target conditions include Acute Kidney Injury (AKI).
What happened to similar drugs?
20 of 20 similar drugs in Acute Kidney Injury (AKI) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03941483 | Phase 2 | Completed |
| NCT04742517 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Kidney Injury (AKI)